The Competition Commission of India (CCI) on 14 November 2026 approved the acquisition of a shareholding in Yatharth Hospital & Trauma Care Services Ltd by Rasmalai Limited, an investment vehicle controlled by funds managed or advised by global private equity firm Advent International.
The clearance from the competition regulator is a key step towards completing Advent's planned ₹3,150-crore investment in the North India-focused hospital chain, which was announced in September.
What the CCI approved
In its announcement, the CCI said the proposed combination relates to the acquisition of "certain shareholding" by Rasmalai Limited, the acquirer, in Yatharth Hospital, the target. The regulator described Rasmalai as an entity incorporated in Cyprus whose principal activity is holding investments, and which currently has no activities or presence in India. It is indirectly controlled by investment funds managed and/or advised by Advent International, L.P. and/or its affiliates, the CCI said.
Yatharth, according to the CCI, operates a network of super-specialty hospitals in India offering comprehensive healthcare services, diagnostics and advanced medical procedures across several specialties.
The CCI's note did not specify the size of the stake. Deals above certain thresholds need the regulator's nod before they can be completed, and the commission typically issues such brief notices once it has cleared a combination.
The deal announced in September
Advent International announced on 17 September 2026 that it would invest ₹3,150 crore of primary capital in Yatharth Hospitals to acquire a significant minority stake of 24.9%. The two sides had signed a definitive agreement, which Advent said was subject to customary closing conditions. Because the money is primary capital, it goes into the company rather than to existing shareholders.
According to Advent's statement, the Tyagi family, Yatharth's promoter, will remain the largest shareholder after the transaction.
Founded in 2008 and listed on the NSE and BSE, Yatharth runs nine multi-speciality hospitals with about 2,800 beds and an announced capacity of around 3,250 beds, Advent said. Its hospitals are spread across the National Capital Region, including Noida, Greater Noida, Noida Extension, Greater Faridabad, New Delhi, Faridabad and Gurugram, along with a hospital at Jhansi-Orchha and a growing presence in Agra.
At the time of the announcement, Yatharth whole-time director Yatharth Tyagi said the investment validated the company's platform and long-term vision, and that Advent brought healthcare expertise and a value-creation mindset. Advent managing director Pankaj Patwari said the firm saw a decade of structural growth ahead in Indian healthcare and wanted to help speed up the company's next phase of growth. Advent director Atin Jain called Yatharth one of North India's most differentiated healthcare platforms.
Why it matters
The approval clears a regulatory hurdle for a sizeable private equity investment in a listed, mid-sized hospital chain. Fresh primary capital of this size gives Yatharth funds to pursue expansion, with its own announced bed capacity already running ahead of the beds it currently operates.
It also underlines continued investor appetite for Indian hospital businesses outside the biggest metros, with Yatharth's footprint spanning the NCR suburbs and smaller cities such as Jhansi and Agra.
What happens next
With the CCI's approval in hand, the transaction can move towards completion once the remaining closing conditions mentioned in the September agreement are met. Shareholders will be watching for company filings on the allotment of shares to Rasmalai and on how the new capital is deployed.
PS · AnjanBorah, CC BY-SA 4.0




